Vardenafil restores erectile function to normal range in men with erectile dysfunction

Journal of Sexual Medicine

Volumn 4, Issue 1, 2007, Pages 152-161

  Padma nathan, Harin ^a   Montorsi, Francesco ^b   Giuliano, François ^c   Meuleman, Eric ^d   Auerbach, Stephen ^e   Eardley, Ian ^f   Mccullough, Andrew ^g   Homering, Martin ^h   Segerson, Thomas ⁱ  

^a The Male Clinic   (United States)

^b Faculty of Medicine   (Italy)

^c BICÊTRE HOSPITAL   (France)

^d Afdeling Urologie   (Netherlands)

^e California Professional Research   (United States)

^f LEEDS GENERAL INFIRMARY   (United Kingdom)

^g NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^h BAYER AG   (Germany)

ⁱ Bayer Inc   (Canada)

Author keywords

Clinical Trials; Erectile Dysfunction; Phosphodiesterase Type 5 Inhibitors; Vardenafil

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PLACEBO; VARDENAFIL;

ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HUMAN; HYPERGLYCEMIA; MALE; META ANALYSIS; PENIS ERECTION; PRIORITY JOURNAL; RHINITIS; SCORING SYSTEM; SEXUAL INTERCOURSE; SIDE EFFECT; SYSTEMATIC REVIEW; THORAX PAIN; TREATMENT OUTCOME;

EID: 33845795681     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2006.00380.x     Document Type: Article

References (15)

1. National Institutes of Health. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993; 270: 83-90.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54-61.
3. Hanson-Divers C, Jackson SE, Lue TF, Crawford SY, Rosen RC. Health outcomes variables important to patients in the treatment of erectile dysfunction. J Urol 1998; 159: 1541-7.
4. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
5. Hellstrom WJG, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H, on behalf of the Vardenafil Study Group. Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763-71.
6. Hatzichristou D, Cuzin B, Martin-Morales A, Burat J, Porst H, Laferriere N, Bandel TJ, Montorsi F, Vardenafil Study Group. Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunction. J Sex Med 2005; 2: 109-16.
7. Donatucci C, Eardley I, Buvat J, Gittelman M, Kell P, Segerson T, Homering M, Montorsi F, Vardenafil Study Group. Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease classification. J Sex Med 2004; 1: 301-9.
8. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26: 777-83.
9. Brock G, Nehra A, Lipshultz LI, Karlin GS, Gleave M, Seger M, Padma-Nathan H. Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol 2003; 170: 1278-83.
10. Cappelleri JC, Siegel RL, Osterloh IH, Rosen RC. Relationship between patient self-assessment of erectile function and the erectile function domain of the international index of erectile function. Urology 2000; 56: 477-81.
11. Montorsi F, Hellstrom W, Valiquette L, Bastuba M, Collins O, Taylor T, Thibonnier M, Eardley I, for the North American and European Vardenafil Groups. Vardenafil provides reliable efficacy over time in men with erectile dysfunction. Urology 2004; 64: 1187-95.
12. Brock G, Porst H, Stief C, Beneke M, Ulbrich E, de Tejada S. Efficacy of vardenafil in a broad population of men with erectile dysfunction irrespective of prior sildenafil use: A retrospective analysis of a 2-year investigation. J Androl 2004; SS: 58.
13. Hatzichristou D, Montorsi F, Buvat J, Laferriere N, Bandel T-J, Porst H, for the European Vardenafil Study Group. The efficacy and safety of flexible-dose vardenafil (Levitra ®) in a broad population of European men. Eur Urol 2004; 45: 634-41.
14. Porst H, Rosen R, Padma-Nathan H, Goldstein I, Giuliano F, Ulbrich E, Bandel T. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial. Int J Impot Res 2001; 13: 192-9.
15. Carson CC, Hatzichristou DG, Carrier S, Lording D, Lyngdorf P, Aliotta P, Auerbach S, Murdock M, Wilkins HJ, McBride TA, Colopy MW, Patient Response with Vardenafil in Slidenafil Non-Responders (PROVEN) Study Group. Erectile response with vardenafil in sildenafil nonresponders: A multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU Int 2005; 96: 466.